TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03539796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dural puncture epidurals (DPE)
Description: Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. A 26g Gertie Marx needle will be inserted through the Touhy epidural needle and used to puncture the dura; clear, free flowing CSF will return in the needle, but no medications will be injected. The 26g spinal needle will be removed, and the epidural catheter inserted through the epidural needle 3-5cm in the epidural space. A test dose with 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine in 5mL increments until a T4 dermatome level is reached. Epidural fentanyl 100mcg will be administered during initial dosing, and morphine-PF 3mg will be given via epidural after delivery of the fetus.
Study: NCT03854487

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Covered mirror
Description: A covered mirror is placed at the midsagittal plane of the patient. The patients in the control group watched the movements of the non-affected arm and moved together with the affected arm behind the covered mirror. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.
Study: NCT03619785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Patient will be positioned supine or in the lateral decubitus position on the side contralateral to the fracture(s). A 3.5 in 20-gauge needle, extension tubing, and a 30 mL syringe loaded with 0.25% bupivacaine and 3 mL of 1% lidocaine loaded in a 5 mL syringe with a 27-gauge needle will be prepared. The ribs, teres minor, latissimus dorsi, and serratus anterior will be identified with bedside US and the site of entry marked along the lateral aspect of the 4th-5th rib. The skin will be sterilized and lidocaine placed at the site of entry. The needle will be introduced at a steep angle and advanced in-plane, under US-guidance, to the plane superficial to the serratus anterior muscle. A test dose of normal saline will confirm proper needle tip placement with opening of the intramuscular layer. Injection with aliquots of 3-5 mL after negative aspiration will continue until 30mL of 0.25% bupivacaine are administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl, morphine, hydromorphone, hydrocodone, acetaminophen, ketorolac, gabapentin, ketamine, ibuprofen
Description: Oral or IV pain medication as needed.
Study: NCT03901378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous administration of pembrolizumab in combination with cisplatin or carboplatin and etoposide in first line metastatic or unresectable high grade neuroendocrine carcinoma:
Study: NCT02862795

Intervention type: PROCEDURE
Group type: OTHER
Intervention: HPV detection in anal canal samples
Description: Additional anal taking during the colonoscopy with cytobrush
Study: NCT02718846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meniace
Description: 6 mg of Meniace tablets were administered 3 times per day after meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meniace
Description: 6 mg of Meniace tablets were administered 3 times per day after meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isobide
Description: an initial dosage of 90 mL of Isobide solution was administered orally 3 times a day after meals
Study: NCT01938170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist
Description: Subjects receiving Flumist vaccine
Study: NCT01595204

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy
Description: Laparoscopy will be performed in each case of clinical/radiological suspicious primary advanced ovarian/peritoneal cancer.~After the introduction of the trocar and the optic, pneumoperitoneum is induced and one or two ancillary trocars are inserted in the iliac fossae bilaterally or where it is possible. A careful complete abdominal and pelvic inspection is carried out in order to identify any possible cause of non optimal cytoreduction. All peritoneal surfaces and the gutters are closely examined and the liver is evaluated by rotating the laparoscope 360° through the umbilical port using grasping forceps as retractors. The small bowel loops and mesentery are evaluated by carefully folding back the various intestinal segments. The pelvis is explored after the bowel loops are retracted in the upper abdomen when possible. At the end of laparoscopy, a PI value is elaborated, based on table given to participant centers.
Study: NCT02293681

Intervention type: DRUG
Intervention: Infliximab
Description: This is an observational study. Participants receiving intravenous infusion of infliximab will be observed.

Intervention type: DRUG
Intervention: NSAIDs
Description: This is an observational study. Participants receiving aspirin, ibuprofen and naproxen as NSAIDs will be observed.

Intervention type: DRUG
Intervention: NSAIDs
Description: This is an observational study. Participants receiving aspirin, ibuprofen and naproxen as NSAIDs will be observed.

Intervention type: DRUG
Intervention: DMARDs
Description: This is an observational study. Participants receiving methotrexate (MTX), sulfasalazine, and thalidomide as DMRADs will be observed.

Intervention type: DRUG
Intervention: DMARDs
Description: This is an observational study. Participants receiving methotrexate (MTX), sulfasalazine, and thalidomide as DMRADs will be observed.
Study: NCT05018338

Intervention type: DEVICE
Intervention: Brain shift monitoring
Description: For use to monitor brain shift during craniotomy
Study: NCT02439385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin/FOLFIRI
Description: Avastin: 5mg/kg iv on day1, every 14 days. Irinotecan: 180 mg /m2 iv on day1, every 14 days. Leucovorin: 200 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil bolus: 400 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil infusion: 1200 mg/m2 iv on day1,2 every 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Dietary supplement of nanostructured lipid curcumin particle 100mg po bid daily
Study: NCT02281058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: self-injected subcutaneous biologic medication
Study: NCT03065530

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Drug: Normal saline control group receive NS after delivery. Drug: butorphanol tartrate PCA: butorphanol tartrate after cesarean section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.03ug/kg/h
Description: Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.03ug/kg/h Dexmedetomidine after cesarean section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.05ug/kg/h
Description: Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.05ug/kg/h Dexmedetomidine after cesarean section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.08ug/kg/h
Description: Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.08ug/kg/h Dexmedetomidine after cesarean section.
Study: NCT03879590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxophylline
Description: Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxophylline
Description: Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
Study: NCT03205969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional mobile game
Description: Functional mobile game for chemotherapy side effect education
Study: NCT02723630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib 10 mg
Description: Treatment 1: low Type-C crystal level \<12%~Treatment 2: reference\* Type-C crystal level 12% to 26%~Treatment 3: high Type-C crystal level \>26%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib 10 mg
Description: Treatment 1: low Type-C crystal level \<12%~Treatment 2: reference\* Type-C crystal level 12% to 26%~Treatment 3: high Type-C crystal level \>26%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib 10 mg
Description: Treatment 1: low Type-C crystal level \<12%~Treatment 2: reference\* Type-C crystal level 12% to 26%~Treatment 3: high Type-C crystal level \>26%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib 10 mg
Description: Treatment 1: low Type-C crystal level \<12%~Treatment 2: reference\* Type-C crystal level 12% to 26%~Treatment 3: high Type-C crystal level \>26%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib 10 mg
Description: Treatment 1: low Type-C crystal level \<12%~Treatment 2: reference\* Type-C crystal level 12% to 26%~Treatment 3: high Type-C crystal level \>26%
Study: NCT03288831

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will drink a mixture of rice water and Tang flavoring one time.
Study: NCT02723630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib 10 mg
Description: Treatment 1: low Type-C crystal level \<12%~Treatment 2: reference\* Type-C crystal level 12% to 26%~Treatment 3: high Type-C crystal level \>26%
Study: NCT01524289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anacetrapib
Description: One oral tablet, orally once daily for 52 weeks
Study: NCT01619904

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Following standard protocol during peri-operative period
Study: NCT00680277

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: spirulina ß-carotene
Description: an acute dose of spirulina up to 5 g

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: spirulina ß-carotene
Description: an acute dose of spirulina up to 5 g

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: spirulina ß-carotene
Description: vitamin A value of spirulina ß-carotene

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: spirulina ß-carotene
Description: vitamin A value of spirulina ß-carotene
Study: NCT02348281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 150mg, po, qd, d1-28
Study: NCT02069535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVANZ Cupressus
Description: AVANZ Cupressus
Study: NCT01246258

Intervention type: OTHER
Intervention: Vestibular evoked myogenic potentials (VEMPs)
Description: Standard test of balance function

Intervention type: OTHER
Intervention: Utricular centrifugation test
Description: Standard test of balance function
Study: NCT01524289

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One oral tablet once daily for 52 weeks
Study: NCT02104180

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urgotul
Description: sterile, hydrocolloid dressing, that consist of a polyester fabric coated with hydrocolloid particles and vaseline

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TulleGras M.S.
Description: Sterile dressing that consists of viscose tissue coated with mineral vaseline
Study: NCT01906840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Turmeric
Study: NCT03567447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: starting with 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
Study: NCT01906840

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01917825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDT-15
Study: NCT04596813

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb 300 mL device
Description: Intra-and postoperative CytoSorb hemoadsorption
Study: NCT01581190

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bananas versus 6% carbohydrate beverage
Description: Trained cyclists (N=14) completed two 75-km cycling time trials (randomized, crossover) while ingesting BAN or CHO (0.2 g/kg carbohydrate every 15 min).
Study: NCT03567447

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: appearing to be 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
Study: NCT01768299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200 mg oral Mifepristone 24 hours before 400 mcg buccal misoprostol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 200 mg oral Mifepristone simultaneously 400 mcg buccal misoprostol
Study: NCT00071773

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified-ETDRS photocoagulation
Description: A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mild Macular Grid photocoagulation
Description: A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
Study: NCT02108730

Intervention type: PROCEDURE
Intervention: restrictive pancreatic resection
Description: Restrictive, spleen-preserving resection of the pancreatic tail by laparoscopy
Study: NCT03567447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: appearing to be 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
Study: NCT03385356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D supplementation of 1000IU vs 4000IU vitamin D per day for four months during winter time, when levels of vitamin D in serum of MS patients are especially low.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D supplementation of 1000IU vs 4000IU vitamin D per day for four months during winter time, when levels of vitamin D in serum of MS patients are especially low.
Study: NCT04205422

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BIPAP
Description: Biphasic Intermittent Positive Airway Pressure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: APRV
Description: Airway Pressure Release Ventilation
Study: NCT03077295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fibre
Description: High fibre/carbohydrate (50% CHO, 35% fat and 15% Protein) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Total dietary fibre will be at least 30g/d for 2000kcal intake and provided as a mixed soluble and insoluble fibre sources to maintain palatability of the diet (e.g. wheat bran, fava bean, lentil, buckwheat).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fibre
Description: High fibre/carbohydrate (50% CHO, 35% fat and 15% Protein) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Total dietary fibre will be at least 30g/d for 2000kcal intake and provided as a mixed soluble and insoluble fibre sources to maintain palatability of the diet (e.g. wheat bran, fava bean, lentil, buckwheat).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein
Description: • High protein diet (30% protein, 35% fat and 35% CHO) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Protein will be a mixed meat matrix to include poultry, fish, red meat, prawns, eggs, dairy. Total dietary fibre will be no more than 15g/d for 2000kcal intake.
Study: NCT01691482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol/salbutamol
Description: Albuterol/salbutamol (daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium
Description: Ipratropium (daily)
Study: NCT03077295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein
Description: • High protein diet (30% protein, 35% fat and 35% CHO) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Protein will be a mixed meat matrix to include poultry, fish, red meat, prawns, eggs, dairy. Total dietary fibre will be no more than 15g/d for 2000kcal intake.
Study: NCT03811951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novolin R
Description: Novolin R is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerol 16 mg/mL, metacresol 3 mg/mL, zinc chloride approximately 7 mcg/mL and water for injection. The pH (potential Hydrogen) is adjusted to 7.4. Hydrochloric acid 2N (concentration) or sodium hydroxide 2N may be added to adjust pH. Novolin R vials are latex-free. The drug substance is being purchased from McKesson.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novolin R
Description: Novolin R is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerol 16 mg/mL, metacresol 3 mg/mL, zinc chloride approximately 7 mcg/mL and water for injection. The pH (potential Hydrogen) is adjusted to 7.4. Hydrochloric acid 2N (concentration) or sodium hydroxide 2N may be added to adjust pH. Novolin R vials are latex-free. The drug substance is being purchased from McKesson.
Study: NCT04219267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: character strengths-based intervention
Description: Character strengths-based intervention (CSI) is one kind of positive psychology interventions. It specifically focuses on character strengths, related activities and exercises assisting individuals to reconnect with their characters and promote self-conceptualization.~The researcher will develop an education module on CSI based on the previous literatures conducted in China and other countries. Before the RCT, this module will be adapted to Chinese participants. During the intervention, participants in the intervention group will be offered the educational module to learn about strengths, comments around the definition of character strengths and examples of specific strengths.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: early memories
Description: In early memories, participants will be instructed to write down something from their early memories every day. The memories could be the things happened several days or many years before the writing day. The memories could be participant' travel experiences or food for a day. There are no strict restrictions on the timing or content of these early events.
Study: NCT01943695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Information
Description: Subjects will be given material regarding cancer and it's impact.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Home Based Training
Description: Patients that elect supervised home based training platform or plan to complete unsupervised training sessions will receive a study kit which includes a heart rate monitor, blood pressure cuff, treadmill and tablet to complete aerobic training requirements. The study kit will be given to the patient upon completion of their baseline testing. The treadmill will be shipped to the patient's home and coordinated by the Ex Onc group. The treadmills are MSK owned equipment that will be deployed to the patient's homes via the vendor TechnoGym. A member of Ex Onc will provide an orientation session for the patient to set up all study kit items. If there is a delay in the patient receiving the treadmill , or any other unforeseen circumstance, patients may be assigned a temporary unsupervised training program until the treadmill is delivered.
Study: NCT00431041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxybutynin immediate release
Description: Oral
Study: NCT01165450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexagon
Description: There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle only
Description: There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
Study: NCT00789386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil (Ultiva ®; Glaxo-Smith-Kline; Vienna, Austria) at an initial dose of 0.24 µg kg-1 min-1 will be applied iv during 60 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied iv as active placebo at a dose of 7.5 µg.kg-1.min-1 over 10 minutes to mimic typical central nervous side effects of remifentanil.